Role of peripheral eosinophilia in acute exacerbation of chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease
Eosinophil
Exacerbation
Forced expiratory volume in one second
Length of hospital stay
Readmission
Systemic steroid
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
06 Jul 2020
06 Jul 2020
Historique:
received:
16
01
2020
revised:
26
04
2020
accepted:
29
06
2020
entrez:
4
8
2020
pubmed:
4
8
2020
medline:
4
8
2020
Statut:
ppublish
Résumé
Eosinophil counts are a promising guide to systemic steroid administration for chronic obstructive pulmonary disease (COPD). To study the role of peripheral eosinophilia in hospitalized patients with acute exacerbation of COPD (AECOPD). From January 2014 to May 2017, patients with AECOPD hospitalized in Taipei Tzu Chi Hospital were retrospectively stratified into two groups according to their peripheral eosinophil count: The EOS group (eosinophil count ≥ 2%) and the non-EOS group (eosinophil count < 2%). Demographics, comorbidities, laboratory data, steroid use, length of hospital stay, and COPD-related readmissions were compared between the groups. A total of 625 patients were recruited, with 176 patients (28.2%) in the EOS group. The EOS group showed a lower prevalence of infection, lower cumulative doses of prednisolone equivalents, shorter length of hospital stay, and higher number of COPD-related readmissions than the non-EOS group. There were significantly linear correlations between eosinophil percentage and number of readmissions and between eosinophil percentage and length of hospital stay ( The study findings suggest that the EOS group had the features of a shorter length of hospital stay, and lower doses of systemic steroids, but more frequent readmissions. The EOS group and lower percent-predicted FEV1 values were risk factors for shorter time to first COPD-related readmission.
Sections du résumé
BACKGROUND
BACKGROUND
Eosinophil counts are a promising guide to systemic steroid administration for chronic obstructive pulmonary disease (COPD).
AIM
OBJECTIVE
To study the role of peripheral eosinophilia in hospitalized patients with acute exacerbation of COPD (AECOPD).
METHODS
METHODS
From January 2014 to May 2017, patients with AECOPD hospitalized in Taipei Tzu Chi Hospital were retrospectively stratified into two groups according to their peripheral eosinophil count: The EOS group (eosinophil count ≥ 2%) and the non-EOS group (eosinophil count < 2%). Demographics, comorbidities, laboratory data, steroid use, length of hospital stay, and COPD-related readmissions were compared between the groups.
RESULTS
RESULTS
A total of 625 patients were recruited, with 176 patients (28.2%) in the EOS group. The EOS group showed a lower prevalence of infection, lower cumulative doses of prednisolone equivalents, shorter length of hospital stay, and higher number of COPD-related readmissions than the non-EOS group. There were significantly linear correlations between eosinophil percentage and number of readmissions and between eosinophil percentage and length of hospital stay (
CONCLUSION
CONCLUSIONS
The study findings suggest that the EOS group had the features of a shorter length of hospital stay, and lower doses of systemic steroids, but more frequent readmissions. The EOS group and lower percent-predicted FEV1 values were risk factors for shorter time to first COPD-related readmission.
Identifiants
pubmed: 32742983
doi: 10.12998/wjcc.v8.i13.2727
pmc: PMC7360705
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2727-2737Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors declared no conflict-of-interest.
Références
Front Med (Lausanne). 2019 Dec 10;6:282
pubmed: 31921866
Eur Respir J. 2014 Dec;44(6):1697-700
pubmed: 25323230
Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2469-78
pubmed: 26648709
Am J Respir Crit Care Med. 2012 Jul 1;186(1):48-55
pubmed: 22447964
N Engl J Med. 1951 Oct 11;245(15):549-55
pubmed: 14875208
J Crit Care. 2010 Dec;25(4):570-5
pubmed: 20435431
Cochrane Database Syst Rev. 2014 Sep 01;(9):CD001288
pubmed: 25178099
Int J Chron Obstruct Pulmon Dis. 2016 Oct 03;11:2467-2473
pubmed: 27757029
Chest. 2016 Aug;150(2):320-8
pubmed: 26851799
Lancet Respir Med. 2016 Sep;4(9):731-741
pubmed: 27460163
Lancet Respir Med. 2019 Aug;7(8):699-709
pubmed: 31122894
Int J Chron Obstruct Pulmon Dis. 2015 Sep 08;10:1837-46
pubmed: 26392758
N Engl J Med. 2017 Oct 26;377(17):1613-1629
pubmed: 28893134
Int J Chron Obstruct Pulmon Dis. 2018 Oct 01;13:3045-3054
pubmed: 30319252
Clin Respir J. 2018 May;12(5):1891-1899
pubmed: 29227024
Med Sci (Basel). 2018 Sep 11;6(3):
pubmed: 30208605
Zhonghua Jie He He Hu Xi Za Zhi. 2019 Jun 12;42(6):426-431
pubmed: 31189228
Pulm Pharmacol Ther. 2016 Apr;37:89-94
pubmed: 26996272
Chest. 2017 Feb;151(2):366-373
pubmed: 27746201
Am J Respir Crit Care Med. 2011 Sep 15;184(6):662-71
pubmed: 21680942
Clin Rev Allergy Immunol. 2016 Apr;50(2):214-27
pubmed: 26690368